Loading
A phase 1/2 trial of Toripalimab in triple-negative breast cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT07281976 by Nanjing Leads Biolabs Co.,Ltd, with 220 participants planned, started 2026-01-27 and due to reach its primary completion in 2027-12-31. Interventions recorded: LBL-024 for Injection, albumin-bound Paclitaxel injection and Toripalimab Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Immune checkpoint inhibitors and the tag pipeline.
Shares Toripalimab, Immune checkpoint inhibitors and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/